EFNS/ENS Guidelines for the treatment of ocular myasthenia

European Journal of Neurology

Volumn 21, Issue 5, 2014, Pages 687-693

  Kerty, E ^a,b   Elsais, A ^a,b   Argov, Z ^c   Evoli, A ^d   Gilhus, N E ^e,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF BERGEN   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Myasthenia gravis; Ocular myasthenia; Treatment

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; VITAMIN D; CHOLINESTERASE INHIBITOR; IMMUNOLOGIC FACTOR;

ARTICLE; ASSISTIVE TECHNOLOGY DEVICE; CLINICAL PROTOCOL; DIPLOPIA; EYE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY (TOPIC); MYASTHENIA; OCULAR MYASTHENIA; PALLIATIVE THERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SYSTEMATIC REVIEW; THYMECTOMY; TREATMENT OUTCOME; FACTUAL DATABASE; MYASTHENIA GRAVIS; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA;

CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; GUIDELINES AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MYASTHENIA GRAVIS; THYMECTOMY;

EID: 84897964914     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12359     Document Type: Article

References (62)

1. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
2. Evoli A, Tonali P, Bartoccioni E, Lo MM. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 1988; 77: 31-35.
3. Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J Neuroophthalmol 2012; 32: 212-215.
4. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987; 505: 472-499.
5. Haines SR, Thurtell MJ. Treatment of ocular myasthenia gravis. Curr Treat Options Neurol 2012; 14: 103-112.
6. Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983; 14: 516-519.
7. Elrod RD, Weinberg DA. Ocular myasthenia gravis. Ophthalmol Clin North Am 2004; 17: 275-309.
8. Daroff RB, Benatar M. Ocular Myasthenia. Myasthenia Gravis and Related Disorder.Totowa, NJ: Humana Press; 2009: 95-104.
9. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246-1252.
10. MacLennan C, Beeson D, Buijs AM, Vincent A, Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann Neurol 1997; 41: 423-431.
11. Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012; 69: 994-1001.
12. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156-162.
13. Sanders DB, Juel VC. MuSK-antibody positive myasthenia gravis: questions from the clinic. J Neuroimmunol 2008; 201-202: 85-89.
14. Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 2005; 62: 1002-1003.
15. Bau V, Hanisch F, Hain B, Zierz S. [Ocular involvement in MuSK antibody-positive myasthenia gravis]. Klin Monbl Augenheilkd 2006; 223: 81-83.
16. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69: 445-451.
17. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259: 427-435.
18. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69: 418-422.
19. Romi F, Suzuki S, Suzuki N, Petzold A, Plant GT, Gilhus NE. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 2012; 259: 1312-1316.
20. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev 2006; 2: CD005081.
21. Ukachoke C, Ashby P, Basinski A, Sharpe JA. Usefulness of single fiber EMG for distinguishing neuromuscular from other causes of ocular muscle weakness. Can J Neurol Sci 1994; 21: 125-128.
22. Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84: 309-333.
23. Barton JJ, Fouladvand M. Ocular aspects of myasthenia gravis. Semin Neurol 2000; 20: 7-20.
24. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
25. Barton JJ. Quantitative ocular tests for myasthenia gravis: a comparative review with detection theory analysis. J Neurol Sci 1998; 155: 104-114.
26. Bhatti MT. Double trouble. Surv Ophthalmol 2003; 48: 347-355.
27. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243-248.
28. Almawi WY, Hess DA, Rieder MJ. Multiplicity of glucocorticoid action in inhibiting allograft rejection. Cell Transplant 1998; 7: 511-523.
29. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006; 63: 60-72.
30. Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signaling. Tissue Antigens 2006; 68: 1-12.
31. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005; 89: 1330-1334.
32. Kaminski HJ, Daroff RB. Treatment of ocular myasthenia: steroids only when compelled. Arch Neurol 2000; 57: 752-753.
33. Kupersmith MJ. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease? J Neurol Sci 2004; 217: 123-124.
34. Agius MA. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol 2000; 57: 750-751.
35. Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996; 53: 802-804.
36. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997; 244: 112-118.
37. Ortiz S, Borchert M. Long-term outcomes of pediatric ocular myasthenia gravis. Ophthalmology 2008; 115: 1245-1248.
38. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008; 71: 1335-1341.
39. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009; 256: 1314-1320.
40. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003; 23: 251-255.
41. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 2004; 217: 131-133.
42. Papapetropoulos TH, Ellul J, Tsibri E. Development of generalized myasthenia gravis in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 1491-1492.
43. Masri MA. The mosaic of immunosuppressive drugs. Mol Immunol 2003; 39: 1073-1077.
44. Rozsa C, Lovas G, Fornadi L, Szabo G, Komoly S. Safety of long-term combined immunosuppressive treatment in myasthenia gravis - analysis of adverse effects of 163 patients. Eur J Neurol 2006; 13: 947-952.
45. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50: 1778-1783.
46. Hildner K, Marker-Hermann E, Schlaak JF, et al. Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Ann N Y Acad Sci 1998; 859: 204-207.
47. Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol 2008; 255: 510-513.
48. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003; 998: 494-499.
49. Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 1998; 30: 2167-2170.
50. Yagi Y, Sanjo N, Yokota T, Mizusawa H. Tacrolimus monotherapy: a promising option for ocular myasthenia gravis. Eur Neurol 2013; 69: 344-345.
51. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82: 970-977.
52. Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11: 97.
53. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15.
54. Kawaguchi N, Kuwabara S, Nemoto Y, et al. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 2004; 224: 43-47.
55. Liu Z, Feng H, Yeung SC, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg 2011; 92: 1993-1999.
56. Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 1985; 48: 332-337.
57. Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 2001; 122: 562-568.
58. Mineo TC, Ambrogi V. Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 2013; 145: 1319-1324.
59. Takanami I, Abiko T, Koizumi S. Therapeutic outcomes in thymectomied patients with myasthenia gravis. Ann Thorac Cardiovasc Surg 2009; 15: 373-377.
60. Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthal Plast Reconstr Surg 2001; 17: 103-110.
61. Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy. Ophthalmology 1996; 103: 623-630.
62. Evans BJ. Orthoptic indications for contact lens wear. Cont Lens Anterior Eye 2006; 29: 175-181.